Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
152 | Publisher: GMR Data
Industry: Pharmaceutical | Report Format: Electronic (PDF)
GMR Data forecasts that revenues for the dermatology drug market will reach $83.2bn in 2026. In this brand new, independently created, pharmaceutical report discover prospects for leading companies and products in the dermatology drugs market today. 5 Reasons why you must read this report today: 1. Dermatology drug manufacturers are enjoying higher revenues than ever before in this niche market and with increasing prevalence of skin diseases, this will continue across the next decade. 2. A number of leading drugs are set to come off of patent across the forecast period. 3. Pipeline products addressing areas of unmet clinical need, especially in the acne, skin infections and skin cancer markets with the potential to become blockbusters, will launch during the forecast period. 4. Understanding the areas of the market in which growth will occur allows for a more tailored approach to expansion, increasing the chances of success. 5. GMR Data’s report gives an in depth and independent view of the leading companies in the dermatology drugs market, ensuring you have all the information needed when moving forward. Included in the report is analysis of the leading companies and geographies in the dermatology drugs market, as well as of the opportunities and threats facing manufacturers. The report has forecasts for all key submarkets in the market as well as for the leading drugs. The primary companies in the market are studied with pipeline products and merger & acquisitions in relation to the dermatology sector. In the report, you will find revenue forecasts to 2026 for the following submarkets in the dermatology drugs market: • Acne • Psoriasis • Alopecia • Skin Cancer • Skin Infections • Atopic Dermatitis The report provides profiles and key existing / pipeline dermatology drugs for the following key companies operating within the dermatology drugs market: • Allergan • Galderma • Valeant pharmaceuticals • Novartis • Merck • Pierre Fabre This independent, 152 page report guarantees you will remain better informed than your competition. With over 150 tables and figures examining the dermatology drugs market, the report gives you a visual, one-stop breakdown of the leading products, submarkets and market leaders market revenue forecasts as well as analysis to 2026, which keeps your knowledge that one step ahead, helping you to succeed. This report is essential reading for you or anyone in the pharmaceutical or health care sectors. Purchasing this report today will help you to recognise those important market opportunities and understand the possibilities there.
Table of Contents The Global Dermatology Market to 2026 Pharmaceutical, commercial and strategic developments in the global dermatology market 2016-2026 Chapter 1 - Executive Summary 1.1 Executive Summary 1.2 Report Description 1.3 Market Segmentation 1.4 Research Methodology Chapter 2 - Introduction to Dermatological Diseases and Prescription Treatments 2.1 Structure and function of human skin 2.2 Dermatological conditions and skin disorders 2.2.1. Acne vulgaris 126.96.36.199. Types and symptoms of acne vulgaris 188.8.131.52. Current prescription (rx) treatments for acne vulgaris 2.2.2. Dermatitis 184.108.40.206. Types and symptoms of dermatitis 220.127.116.11. Current prescription (rx) treatments for dermatitis 2.2.3. Psoriasis 18.104.22.168. Types and symptoms of psoriasis 22.214.171.124. Current prescription (rx) treatments for psoriasis 2.2.4. Skin cancer 126.96.36.199. Types and symptoms of skin cancer 188.8.131.52. Current prescription (rx) treatments for skin cancer 2.2.5. Skin infections 184.108.40.206. Types and symptoms of skin infections 220.127.116.11. Current prescription (rx) treatments for skin infections 2.2.6. Rosacea 18.104.22.168. Types and symptoms of rosacea 22.214.171.124. Current prescription (rx) treatments for rosacea 2.2.7. Alopecia 126.96.36.199. Types and symptoms of alopecia 188.8.131.52. Current prescription (rx) treatments for alopecia Chapter 3 - Current trends and developments in the global dermatology market 3.1 Current trends, challenges and developments 3.2 Mergers and Acquisitions Chapter 4 - Global dermatological drugs market and forecast 2016 - 2026 4.1 Global acne vulgaris market, 2016 - 2026 4.1.1. Key trends in the global acne vulgaris market 4.1.2. Market size and forecast 4.1.3. Major drugs and forecast 184.108.40.206. Solodyn market and forecast 220.127.116.11. Doryx market and forecast 18.104.22.168. Epiduo market and forecast 4.1.4. Acne vulgaris - phase iii drugs pipeline forecast 22.214.171.124. Onexton (valeant) 126.96.36.199. Epiduo forte (galderma) 188.8.131.52. Sarecycline (actavis) 4.1.5. Acne vulgaris - phase ii drugs pipeline forecast 184.108.40.206. Drm01 (dermira) 220.127.116.11. Fmx101 (foamix) 18.104.22.168. Sb204 (novan therapeutics) 22.214.171.124. Seb002 (sebacia) 126.96.36.199. Mtc896 (mimetica) 4.2 Global psoriasis market, 2016 - 2026 4.2.1. Key trends in the global psoriasis market 4.2.2. Market size and forecast 4.2.3. Major drugs and forecast 188.8.131.52. Stelara (psoriasis) market and forecast 184.108.40.206. Enbrel (psoriasis) market and forecast 220.127.116.11. Humira (psoriasis) market and forecast 18.104.22.168. Otezla (psoriasis) market and forecast 22.214.171.124. Cosentyx (psoriasis) market and forecast 126.96.36.199. Taltz (psoriasis) market and forecast 188.8.131.52. Piclidenoson (psoriasis) market and forecast 4.2.4. Psoriasis - phase iii drugs (injectable biologics) pipeline forecast 184.108.40.206. Bi 655066 (boehringer ingelheim) 220.127.116.11. Guselkumab (janssen) 18.104.22.168. Tildrakizumab (sun pharma) 4.2.5. Psoriasis - phase iii drugs (injectable biologics) pipeline forecast 22.214.171.124. Cimzia (ubc) 126.96.36.199. Brodalumab (astra-zeneca/valeant) 4.2.6. Psoriasis - phase ii drugs (injectable biologics) pipeline forecast 188.8.131.52. Tregalizumab (biotest ag) 184.108.40.206. Namilumab (takeda pharmaceuticals) 220.127.116.11. Imo-8400 (idera pharmaceuticals) 4.2.7. Psoriasis - phase ii (10) drugs (orally administered) pipeline forecast 4.3 Global alopecia market, 2016 - 2026 4.3.1. Key trends in the global alopecia market 4.3.2. Market size and forecast 4.3.3. Major drugs and forecast 18.104.22.168. Propecia market and forecast 4.3.4. Alopecia - phase iii drugs pipeline forecast 22.214.171.124. Bimatoprost (allergan) 126.96.36.199. Sm04554 (samumed) 4.3.5. Alopecia - phase ii (2) drugs pipeline forecast 4.4 Global skin cancer market, 2016 - 2026 4.4.1. Key trends in the global skin cancer market 4.4.2. Market size and forecast 4.4.3. Major drugs and forecast 188.8.131.52. Yervoy market and forecast 184.108.40.206. Zelboraf + cotellic market and forecast 220.127.116.11. Tafinlar + mekinist market and forecast 18.104.22.168. Keytruda market and forecast 22.214.171.124. Opdivo, opdivo + yervoy market and forecast 126.96.36.199. Imlygic market and forecast 188.8.131.52. Erivedge market and forecast 184.108.40.206. Odomzo market and forecast 4.4.4. Skin cancer - phase iii (12) drugs pipeline forecast 4.4.5. Skin cancer - phase ii (53) drugs pipeline forecast 4.5 Global skin infections market, 2016 - 2026 4.5.1. Key trends in the global skin infections market 4.5.2. Market size and forecast 4.5.3. Major drugs and forecast - csssis 220.127.116.11. Cubicin market and forecast 18.104.22.168. Zyvox market and forecast 22.214.171.124. Sivextro market and forecast 126.96.36.199. Orbactiv market and forecast 188.8.131.52. Dalvance market and forecast 184.108.40.206. Tygacil market and forecast 220.127.116.11. Teflaro market and forecast 4.5.4. Major drugs and forecast - onychomycosis 18.104.22.168. Kerydin market and forecast 22.214.171.124. Jublia market and forecast 4.5.5. Skin infections - phase iii (11) drugs (csssis) pipeline forecast 4.5.6. Skin infections - phase iii (3) drugs (onychomycosis) pipeline forecast 4.5.7. Skin infections - phase ii (3) drugs (onychomycosis) pipeline forecast 4.6 Global atopic dermatitis market, 2016 - 2026 4.6.1. Key trends in the global atopic dermatitis market 4.6.2. Market size and forecast 4.6.3. Major drugs and forecast 4.6.4. Atopic dermatitis - phase iii drugs pipeline forecast 126.96.36.199. Dupilumab (sanofi/regeneron) 188.8.131.52. Crisaborole (anacor/pfizer) 184.108.40.206. Zpl-389 (ziarco pharma) 220.127.116.11. Nanocyclo (immune pharmaceuticals) 4.6.5. Atopic dermatitis - phase ii drugs (orally/topically administered) pipeline forecast 18.104.22.168. Tofactinib/xeljanz (pfizer) 22.214.171.124. Zpl-521 (ziarco pharma) 126.96.36.199. Opa-15406 (otsuka/medimetriks) 4.6.6. Atopic dermatitis - phase ii drugs (injectable moabs) pipeline forecast 188.8.131.52. Bertilimumab (immune pharmaceuticals) 184.108.40.206. Tralokinumab (leo pharma/astra-zeneca) 220.127.116.11. Nemolizumab (chugai pharmaceuticals) 18.104.22.168. Lebrikizumab (roche/genentech) 4.7 Global rosacea market, 2016 - 2026 4.7.1. Key trends in the global rosacea market 4.7.2. Market size and forecast 4.7.3. Major drugs and forecast 22.214.171.124. Finacea gel + finacea foam (bayer/foamix) 126.96.36.199. Mirvaso (galderma) 188.8.131.52. Soolantra (galderma) 184.108.40.206. Oracea (galderma) 4.7.4. Rosacea - phase iii drugs pipeline forecast 220.127.116.11. Azultro (allergan) Chapter 5 - Leading companies in the global dermatology market 5.1 Allergan (Allergan plc.) 5.2 Galderma (Nestle Skin Health) 5.3 Valeant pharmaceuticals 5.4 Novartis 5.5 Merck & co. inc. 5.6 Pierre Fabre Chapter 6 - Key national markets in the global dermatology sector, 2016 - 2026 6.1 US Dermatological Drugs Market and Forecast, 2016 - 2026 6.2 UK Dermatological Drugs Market and Forecast, 2016 - 2026 6.3 France Dermatological Drugs Market and Forecast, 2016 - 2026 6.4 Germany Dermatological Drugs Market and Forecast, 2016 - 2026 6.5 Spain Dermatological Drugs Market and Forecast, 2016 - 2026 6.6 Italy Dermatological Drugs Market and Forecast, 2016 - 2026 6.7 Japan Dermatological Drugs Market and Forecast, 2016 - 2026 6.8 Row Dermatological Drugs Market and Forecast, 2016 - 2026 Chapter 7 - Expert opinion 7.1 Bristol-Myers Squibb 7.2 Johnson & Johnson Appendix: skin cancer - phase iii and phase ii drugs pipeline
Our library has over 100000 reports on 1000s of topics
Over 100+ Fortune 500 companies rely on us
90,000+ people come to us for insights every month
Toll Free: 1-888-928-9744
Email: [email protected]
Speak to the report author to design an exclusive study to serve your research needs.
A testimonial for service excellence represented in the form of BBB "A" Accreditation.
Your personal and confidential information is safe and secure.